Bladder Cancer Clinical Trials

Find Bladder Cancer Clinical Trials Near You

Establishment and Promotion of an AI-Based Early Warning System for Prostate and Bladder Cancer Screening in the Male Community Population of Beijing

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Observational
SUMMARY

Prostate cancer is one of the most common malignancies in the male genitourinary system, and it is also the cancer with the fastest-growing incidence and mortality rates among men in China. Although prostate cancer screening can significantly reduce mortality, China has not yet established a well-developed screening system, which is one of the reasons why its mortality rate remains notably higher than that of Western countries. The primary objective of this project is to establish an efficient screening-diagnosis-treatment pathway, beginning with screening in community hospitals, followed by definitive diagnosis in secondary hospitals, and finally treatment in tertiary hospitals. Additionally, the project aims to achieve multi-institutional and multi-terminal sharing of disease information as well as dynamic monitoring and follow-up. The feasibility and effectiveness of this model will be validated through statistical analysis of the data.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 85
Healthy Volunteers: t
View:

• Male community residents aged 50 years or older;

⁃ Life expectancy \> 10 years and ECOG performance status of 0-2;

⁃ Permanent residents of Beijing who are willing to cooperate with researchers in the screening process, complete required tests and questionnaires, and participate in subsequent follow-up;

⁃ Support for the research project and provision of signed informed consent.

Locations
Other Locations
China
Department of Urology, Peking University First Hospital, Beijing, 100034
RECRUITING
Beijing
Contact Information
Primary
Zejin Ou
1522065106@qq.com
17310018392
Time Frame
Start Date: 2024-01-01
Estimated Completion Date: 2027-12-01
Participants
Target number of participants: 3000
Related Therapeutic Areas
Sponsors
Leads: Peking University First Hospital

This content was sourced from clinicaltrials.gov